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Pharmacogenetic Interactions Between
ngiotensin-Converting Enzyme Inhibitor
herapy and the Angiotensin-Converting
nzyme Deletion Polymorphism
n Patients With Congestive Heart Failure
ennis M. McNamara, MD,* Richard Holubkov, PHD,† Lisa Postava, MBA,* Karen Janosko, MSN,*
uy A. MacGowan, MD,* Michael Mathier, MD,* Srinivas Murali, MD,*
rthur M. Feldman, MD, PHD,‡ Barry London, MD, PHD*
ittsburgh and Philadelphia, Pennsylvania; and Salt Lake City, Utah
OBJECTIVES We evaluated the interaction of angiotensin-converting enzyme (ACE) inhibitor therapy
with the effect of the ACE D/I polymorphism on heart failure survival.
BACKGROUND The ACE deletion allele, ACE-D, is associated with increased ACE activity. The utilization
of ACE genotyping to predict the impact of ACE inhibitor dose has not been previously
evaluated.
METHODS We prospectively studied 479 subjects with systolic dysfunction (left ventricular ejection
fraction 0.25  0.08). Subjects were divided on the basis of ACE inhibitor therapy into low
dose (50% of target dose, n  227), standard (high) dose (50%, n  201), or those
receiving angiotensin receptor antagonists (n  51). Patients were genotyped for the ACE
D/I polymorphism, followed to the end point of death or cardiac transplantation, and
transplant-free survival compared by genotype.
RESULTS The ACE-D allele was associated with an increased risk of events (p  0.026). In analysis by
ACE inhibitor dose, this effect was primarily in the low-dose group (1-year percent event-free
survival: II/ID/DD 86/77/71, 2-year 79/66/59, p 0.032). In the standard-dose group,
the impact was markedly diminished (1-year: II/ID/DD  91/81/80, 2-year: 77/70/71, p 
0.64). The impact of beta-blockers and high dose ACE inhibitors was greatest in subjects
with the ACE DD genotype (p 0.001) and was less apparent with the II and ID genotypes
(p  0.38).
CONCLUSIONS Higher doses of ACE inhibitors diminished the impact of the ACE-D allele, and the benefits
of beta-blockers and high-dose ACE inhibitors appeared maximal for DD patients.
Determination of ACE genotype may help target therapy for patients with heart
failure. (J Am Coll Cardiol 2004;44:2019–26) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.048Cardiology Foundation
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Areatment with angiotensin-converting enzyme (ACE)
nhibitors remains the cornerstone of heart failure ther-
py (1). More recently, beta-adrenergic receptor antago-
ists (beta-blockers) have been demonstrated to improve
urvival in chronic heart failure (2,3). The efficacy of
hese therapies has been demonstrated in multicenter
rials for large populations; however, significant hetero-
eneity may exist in the benefits to individual subjects.
re-treatment assessment of therapeutic efficacy would
llow tailoring of therapy to optimize outcomes, but at
resent the tools to define which individuals obtain
aximal benefit are limited.
Despite the benefits of ACE inhibition, efforts to further
mprove heart failure survival by increasing neurohormonal
From the *Cardiovascular Institute, University of Pittsburgh Medical Center,
ittsburgh, Pennsylvania; †Department of Family and Preventive Medicine, School
f Medicine, University of Utah, Salt Lake City, Utah; and ‡Department of
edicine, Thomas Jefferson Medical Center, Philadelphia, Pennsylvania. This study
as supported in part by grants from the National Heart, Lung, and Blood Institute,
ontracts HL 69912 (to Dr. McNamara) and HL 62300 (to Dr. London).p
Manuscript received November 22, 2003; revised manuscript received August 13,
004, accepted August 17, 2004.lockade, either with high-dose ACE inhibitors (4) or the
ddition of angiotensin receptor blockers (ARB) (5), have
et with limited success. The role of genetic heterogeneity
n modulating the effectiveness of these pharmacologic
nterventions has not been explored. A common polymor-
hism exists in intron 16 of the ACE gene in which the two
lleles differ on the presence or absence of a 287 base-paired
nsertion (I  insertion; D  deletion) (6,7). The D allele
s associated with higher ACE activity (8–10) and has been
reviously associated with poorer survival for patients with
ongestive heart failure (11). The ACE DD genotype
elineates a large patient subset, one-third of the general
opulation, known to have higher levels of angiotensin
ctivation. We have previously reported a pharmacogenetic
nteraction of the ACE D/I polymorphism with beta-
locker therapy (12); however, the impact of ACE inhibitor
ose has not been evaluated. In a population with heart
ailure, we sought to evaluate the pharmacogenetic interac-
ion of the ACE D/I polymorphism with the impact of
CE inhibitor dose on clinical outcomes, and to explore the
otential use of ACE genotype to target therapy.
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tudy population. The Institutional Review Board of the
niversity of Pittsburgh Medical Center approved this
tudy. A series of 479 patients with heart failure resulting
rom systolic dysfunction referred to the Cardiomyopathy
linic at the University of Pittsburgh Medical Center were
ecruited into a study of Genetic Risk Assessment of
ardiac Events (GRACE) between April 1996 and January
001. Preliminary analysis of the first 328 subjects has been
reviously reported (12). Informed consent was obtained
nd peripheral blood drawn for deoxyribonucleic acid
DNA) isolation and genotyping. At entry, demographic
nformation, New York Heart Association (NYHA) func-
ional class, and medical therapy were recorded. Patients
ere prospectively followed to an end point of either death
r cardiac transplantation. Medical personnel participating
n management and follow-up were unaware of the geno-
ype status of individual subjects.
In all patients, the most recent clinical assessment dem-
nstrated left ventricular systolic dysfunction, defined as left
entricular ejection fraction (LVEF) 0.45 (n  449) or
ualitative assessment documenting moderate to severe left
entricular dysfunction (n  30). The LVEF was estimated
y radionuclide scan in 177 patients (37.0%), left ventricular
ngiography in 27 (5.6%), and by echocardiography in 275
57.4%). Patients with angiographic evidence of coronary
isease (defined as 50% stenosis of a major epicardial
oronary artery), or a noninvasive assessment consistent
ith ischemia or previous infarction were classified as
schemic.
enotyping of the ACE polymorphism. Genomic DNA
as extracted from peripheral blood with a Pure Gene Kit,
entra Systems, Inc. (Minneapolis, Minnesota). The ACE
enotyping was performed using the method of Lindpaint-
er et al. (13); primers 5=GCC CTG CAG GTG TCT
CA GCA TGT 3= and 5= GGA TGG CTC TCC CCG
CT TGT CTC 3= were used to amplify the D and I
lleles, resulting in 319 base pair (bp) and 597-bp products,
espectively. Polymerase chain reactions were run for 35
ycles: 30 s at 94°, 45 s at 56°, and 2 min at 72°. The product
as subjected to electrophoresis in a 1.5% agarose gel and
tained with ethidium bromide. Given preferential amplifi-
ation of the D allele in heterozygous samples, samples
ound to have the DD genotype were re-amplified using
nsertion-specific primers: 5= TGG GAC CAC AGC
CC CGC CAC TAC 3=, and 5= TCG CCA GCC CTC
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ARB  angiotensin receptor blocker
CI  confidence interval
LVEF  left ventricular ejection fraction
NYHA  New York Heart AssociationCA TGC CCA TAA 3= and identical polymerase chain teaction conditions except for an annealing temperature of
7°. Evaluation of these products on a 1.5% agarose gel
evealed a 335-bp product in the presence of an I allele.
edical therapy classification. For both the beta-blocker
nd ACE dose, patients were categorized on the basis of
heir therapy at time of study entry. For analysis of the
ffect of ACE inhibition, subjects whose daily dose of
CE inhibitor therapy at the time of study entry was
50% of target dose based on published guidelines
14 –16) were classified as “high-dose,” whereas those
hose daily dose was 50% were classified as “low-dose.”
atients on angiotensin receptor antagonists were ex-
luded from the ACE dose analysis but included in the
verall outcome analysis.
ollow-up and outcomes analysis. Patients were followed
rospectively to the end point of death or cardiac transplan-
ation. The effect of the ACE-D allele on events-free
urvival was analyzed for the entire cohort, and then
eparately in subsets based on medical therapy class (beta-
lockers vs. no beta-blockers; ACE low dose vs. high dose).
or the analysis of the impact of therapy within genotype
lass, the four neurohormonal treatment strategies (1: beta-
lockers plus high-dose ACE inhibitor; 2: beta-blockers
lus low dose; 3: no beta-blockers plus high dose; and 4: no
eta-blockers plus high dose) were analyzed for the subjects
ith the ACE DD genotype, and then for the remainder (II
nd ID subjects combined).
tatistical analysis. Results are presented as mean values
D. Continuous baseline characteristics were compared
onparametrically based on ordered genotype status using
he Jonckheere-Terpstra test (17), whereas these compari-
ons were made between two groups using the Wilcoxon
ank-sum test. The Pearson chi-square test was used to
ompare distributions of binary variables between two
roups. The Mantel-Haenszel chi-square test was used to
ompare distributions of all categorical variables by ordered
enotype status, as well as of ordered categorical variables
NYHA functional class) between two groups. For outcome
nalysis, Kaplan-Meier event-free survival curves were con-
tructed. The log-rank test was used for comparison of
urvival curves. In the case of multiple ordered subgroups
such as those defined by genotype status), a log-rank test
ncorporating linear trend across genotype levels was used
or testing equality of event-free survival. Cox regression
nalysis was used to quantify the relative risk of events over
ime; the significance of reported coefficients was assessed
y the Wald test. For each analysis, the statistical interac-
ion of drug therapy with ACE genotype class was assessed
sing a Cox regression model with linear ordering of
elevant categories. Specifically, for analysis of survival by
CE genotype, gene dose was utilized as the ordered
ariable (assuming an intermediate effect for heterozygotes),
hereas for analysis of the impact of therapy within geno-ype class, degree of neurohormonal blockade was used.
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aseline demographics and clinical characteristics. The
emographic and baseline clinical characteristics by geno-
ype are listed in Table 1. The mean age of the cohort was
5.7  12.0 years. The population was 72% male, 91%
hite, and 49% ischemic. Genotyping classified 18.6% of
atients (n  89) as homozygotes for the I allele, 50.7% (n
243) as heterozygotes, and 30.7% (n  147) as homozy-
otes with D allele. No significant differences in medical
herapy were detected among the three genotype subgroups.
lassification by medical therapy. HIGH- VERSUS LOW-
OSE ACE INHIBITOR THERAPY. Based on ACE inhibitor
ose at entry, 42% (n  201) of subjects were classified in
he high-dose subset. This treatment group could be more
ccurately characterized as the “standard” dose therapy
ubset as the majority were at (n  121, 60%) or above (n
56, 28%) target doses defined by heart failure treatment
uidelines. The remaining subjects in the higher dose
reatment subset were on 75% (n  17, 9%) or 67% (n  7,
%) of the target dose. Forty-seven percent of subjects (n 
27) were classified in the low-dose group, including 5% (n
25) on neither an ACE inhibitor nor an ARB. The
emaining subjects (n  51, 11%) were on ARBs. Nine
ercent of subjects (n  43) were treated with the aldoste-
one receptor antagonist (spironolactone) at the time of
ntry.
The demographics and clinical characteristics by dose
lass are listed in Table 2. Patients on low-dose therapy
ere slightly older (mean age 56.5  12.1 years vs. 54.1 
2.2 years, p  0.050). In addition, the percentage of
atients with an ischemic etiology was higher in the
ow-dose group than in the high-dose group (56.8% vs.
9.3%, p  0.001). The NYHA functional class, LVEF,
nd the percentage of patients receiving beta-blockers were
imilar between groups (Table 2). In addition, the percent-
ge of patients with systolic or diastolic hypertension and
he mean diastolic and systolic blood pressures were all
omparable in the higher dose and low-dose groups. The
able 1. Patient Characteristics by Genotype
II
(n  89)
ge (yrs) 55.4  12.2
emale (%) 25.8
aucasian (%) 91.0
YHA class, I/II/III/IV (%) 0.0/44.9/48.3/6.7 4
schemic (%) 48.3
VEF (n  449) 0.25 0.07
a (mg/dl) (n  316) 138.2  3.4
r (mg/dl) (n  318) 1.32  0.50
nitial medical therapy
ACE inhibitor (%) 84.3
ARB (%) 9.0
eta-blocker (%) 41.6
alues are mean  SD or percent of patients. No significant differences were detect
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker; Cr
New York Heart Association.ajority of subjects were taking either captopril, enalapril, ar lisinopril; mean doses for the low- and high-dose class are
isted in Table 3.
For 85% (299 of 359) of those subjects alive and not
ransplanted at one year, medical therapy was reassessed. At
ne year, 13% of subjects had moved from the low to the
igher dose class, 8% from higher to low dose, whereas 5%
witched from an ACE inhibitor to an ARB. The majority
f subjects (74%) remained in the same dosage class at one
ear, suggesting that in early follow-up entry dosage was
eflective of treatment strategy.
ETA-BLOCKERS. Overall 202 patients (42%) were receiv-
ng beta-blocker therapy at study entry and 277 (58%) were
ot taking beta-blockers. Of those receiving therapy, 55%
ere taking carvedilol (mean daily dose 31  24 mg), 39%
etoprolol (59  34 mg), and 6% other. Patients taking
eta-blockers were slightly younger (mean age 54.4  12.2
s. 56.7  11.7 years, p  0.03) and had a higher mean
VEF (0.26  0.09 vs. 0.24  0.08, p  0.03).
utcomes by ACE genotype. EVENT-FREE SURVIVAL: EN-
IRE COHORT. For patients alive and transplant-free at last
ollow-up, median follow-up was 33 months (range 3 to 62
onths). During the course of follow-up there were 194
ID
 243)
DD
(n  147)
All Patients
(n  479)
.4  12.1 56.5  11.7 55.7  12.0
30.9 25.9 28.4
91.4 90.5 91.0
.9/48.1/2.5 1.4/40.1/50.3/8.2 2.7/43.4/48.9/5.0
46.1 55.1 49.3
4  0.09 0.25  0.09 0.25  0.08
.9  3.5 138.8  3.7 138.7  3.6
4  0.57 1.40  0.77 1.36  0.64
86.0 81.0 84.1
9.9 12.9 10.6
42.0 42.9 42.2
ween the three genotype subgroups.
m creatinine; LVEF left ventricular ejection fraction; Na serum sodium; NYHA
able 2. Patient Characteristics by ACE Inhibitor Dose
High Dose
(n  201)
Low Dose
(n  227)
ge (yrs) 54.1  12.2 56.5  12.1*
emale (%) 27.9 29.5
aucasian (%) 90.0 92.1
YHA class, I/II/III/IV (%) 4.5/44.3/46.8/4.5 1.3/44.5/48.5/5.7
schemic (%) 39.3 56.8†
eta-blocker (%) 41.8 42.7
VEF (n  402) 0.25  0.08 0.24  0.08
a (mg/dl) (n  275) 138.7  3.5 138.6  3.6
r (mg/dl) (n  277) 1.35  0.57 1.38  0.71
P sys (mm Hg) (n  427) 114 17 112  17
P dia (mm Hg) (n  426) 71 11 71  10
alues are mean SD or percent of patients. *p 0.050; †p 0.001 for significance
f the distributions of this variable between the two groups.(n
55
.5/44
0.2
138
1.3
ed betBP dia  diastolic blood pressure; BP sys  systolic blood pressure; other
bbreviations as in Table 1.
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ACE Polymorphism and ACE Inhibitor Therapy November 16, 2004:2019–26vents, including 137 deaths and 57 transplants. The ma-
ority of the deaths were cardiac in etiology (94%), with
eart failure deaths accounting for 46% and sudden death
9%. The cause of death did not differ significantly by
enotype subset. The D allele was associated with poorer
ransplant-free survival (1-year percent transplant-free by
enotype II/ID/DD  89/80/74: 2-year  77/69/62; p 
.026 (Fig. 1A). Corresponding Cox regression analysis
ith the II genotype as the reference category found a
elative risk for heterozygotes of 1.28 (95% confidence
nterval [CI] 0.86 to 1.92, p  0.23) and a significantly
ncreased risk among patients with the DD genotype of 1.58
95% CI 1.04 to 2.40, p  0.032). When analyzed sepa-
ately by etiology of heart failure, the effect of the ACE-D
llele on survival appeared similar in non-ischemic and
schemic subsets (non-ischemic: 1-year percent transplant-
ree by genotype II/ID/DD  93/84/81, 2-year  87/74/
1, p  0.35; ischemic: 1-year  84/76/69, 2-year 
7/63/56, p  0.08).
ETA-BLOCKER THERAPY. Analysis demonstrated a signif-
cant pharmacogenetic interaction with beta-blocker utili-
ation, as previously reported in a smaller subset (12). The
dverse effect of the ACE-D allele on event-free survival
as strongly evident in subjects not receiving beta-blockers
1-year percent transplant-free survival II/ID/DD 88/78/
3; 2-year  80/65/51; p  0.004) (Fig. 1B) with a relative
isk among heterozygotes of 1.28 (95% CI 0.78 to 2.10, p
.33) and among the DD homozygotes of 1.98 (95% CI
.18 to 3.30, p  0.009). For patients taking beta-blockers,
he ACE deletion appeared to have no impact on outcomes
1-year II/ID/DD  89/84/89; 2-year  73/77/78; p 
.97) (Fig. 1C).
CE INHIBITOR HIGH VERSUS LOW DOSE. The interaction
f ACE dose and genetic risk was evaluated through a
omparison of the impact of the ACE-D allele on outcomes
n the two ACE dose subsets. The adverse effect of the D
llele was primarily evident in the low-dose therapy group
1-year percent transplant-free survival II/ID/DD 86/77/
1; 2-year  79/66/59; p  0.032) with a borderline
ncrease in the relative risk for heterozygotes to 1.67 (95%
I 0.86 to 3.21; p  0.13) and a significant increase among
atients with the DD genotype to 2.07 (95% CI 1.06 to
.05, p  0.03) (Fig. 2A). The adverse impact of the D
Table 3. ACE Inhibitor Utilization
Drug (Target*)
Overall Cohort
n (%)
Mean Dose
(mg)
Enalapril (20 mg) 146 (36.2) 17  13
Captopril (150 mg) 122 (30.3) 82  49
Lisinopril (20 mg) 101 (25.1) 18  12
Others 34 (8.4)
*References 14, 15, and 16; mean dose indicates total daily
ACE  angiotensin-converting enzyme.llele on outcomes was markedly diminished for those in the
0
tigh-dose group (1-year II/ID/DD  91/81/80; 2-year 
7/70/71; p  0.64) (Fig. 2B).
Although the power was limited for analysis by etiology,
he impact of ACE inhibitor dose on the effect of the
CE-D allele on survival appeared similar in ischemic and
on-ischemic subsets (low-dose ACE inhibitors, non-
schemic: 1-year percent transplant-free by genotype II/
D/DD  93/81/79, 2-year  93/73/65, p  0.08; low-
igure 1. (A) Overall transplant-free survival by angiotensin-converting
nzyme (ACE) genotype (n  479, p  0.026). (B) Transplant-free
urvival by ACE genotype with no beta-blocker therapy (n  277, p 
Low-Dose Group High-Dose Group
(%)
Mean Dose
(mg) n (%)
Mean Dose
(mg)
31.2) 8  3 83 (41.3) 24  13
39.1) 51  23 43 (21.4) 129  26
(24.3) 8  3 52 (25.9) 27  11
(5.4) 23 (11.4)n
63 (
79 (
49
11.004). (C) Transplant-free survival by ACE genotype with beta-blocker
herapy (n  202, p  0.97).
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November 16, 2004:2019–26 ACE Polymorphism and ACE Inhibitor Therapyose ischemic: 1-year  81/73/70, 2-year  71/60/54, p 
.22; high-dose ACE inhibitors, non-ischemic: 1-year per-
ent transplant-free by genotype II/ID/DD  96/84/86,
-year  87/73/81, p  0.81; higher dose ischemic: 1-year
82/76/73, 2-year  60/65/58, p  0.44).
FFECT OF ACE DOSE IN SUBJECTS NOT RECEIVING BETA-
LOCKERS. The analysis of ACE dose was repeated in
he subset of patients not taking beta-blockers (excluding
0 patients taking ARBs, n  247). In the subgroup
eceiving minimal neurohormonal blockade (low-dose
CE and no beta-blockers, n  130), the effects of the D
llele on outcomes were dramatically increased (1-year
I/ID/DD  87/74/55; 2-year  77/61/43, p  0.005)
Fig. 3A), with a relative risk for heterozygotes of 1.62
95% CI 0.74 to 3.52, p  0.23) and for DD homozy-
otes of 2.75 (95% I 1.25 to 6.08, p  0.012). High-dose
CE inhibitor therapy (n  117) still diminished the
mpact of the ACE-D allele (1-year  88/78/72; 2-year
80/67/61, p  0.47) (Fig. 3B).
utcomes by treatment strategy. RELATIVE RISK OF
VENT BY THERAPY. Analysis of the entire cohort suggests
oorer event-free survival for subjects with ACE DD
enotype; however, this subset also appears to obtain max-
mal benefit from medical intervention. The relative risks of
igure 2. (A) Transplant-free survival by angiotensin-converting enzyme
ACE) genotype: low-dose ACE inhibitor (n  227, p  0.032). (B)
ransplant-free survival by ACE genotype: high-dose ACE inhibitor (n
01, p  0.64).vents (death or transplant) by therapy are listed in Table 4. dverall, beta-blocker therapy was associated with a signif-
cant reduction in event rate (29%, p  0.03). Within
enotype class, beta-blockers dramatically reduced the event
ate for DD subjects (53%, p  0.004), but not for patients
ho were ID (15%, p 0.46) or II (3%, p 0.94). Overall,
nly a modest nonsignificant reduction in event-free survival
as evident with high-dose ACE therapy when compared
ith low-dose (14%, p  0.33). However, a similar trend
oward greater benefit is evident in the DD subgroup,
articularly in those not treated with beta-blockers (38%,
 0.14).
MPACT OF HEART FAILURE THERAPY ON TRANSPLANT-
REE SURVIVAL. Evaluation of treatment strategy within
he DD genotype class suggests that increasing neurohor-
onal blockade is of significant clinical benefit in this
ubset. Event-free survival was poorest on low-dose ACE
nhibitors alone (1-year and 2-year percent transplant-free
urvival  55/43), intermediate on high-dose ACE inhib-
tors alone (1-year/2-year  72/61), and best for those
eceiving beta-blockade regardless of ACE inhibitor dose
beta-blockers plus low-dose ACE  89/77; beta-blockers
lus high-dose ACE  91/86). An ordered comparison of
reedom from event curves (Fig. 4A) of increasing neuro-
ormonal blockade (1  low-dose ACE alone; 2  high-
igure 3. (A) Transplant-free survival by angiotensin-converting enzyme
ACE) genotype: low-dose ACE inhibitor therapy with no beta-blockers
n  130, p  0.005). (B) Transplant-free survival by ACE genotype:
igh-dose ACE inhibitor therapy with no beta-blockers (n  117, p 
.47).ose ACE alone; 3  low-dose plus beta-blockers; and 4 
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ACE Polymorphism and ACE Inhibitor Therapy November 16, 2004:2019–26igh-dose plus beta-blockers) demonstrates a significant
enefit of increasing therapy for subjects with the DD
enotype (p  0.001).
In contrast, for the remaining subjects (ID and II
ombined), neurohormonal treatment strategy appeared to
ave less impact on event-free survival (low-dose ACE
lone 1-year and 2-year percent transplant-free survival 
7/65, high dose alone  81/71, low-dose plus beta-
lockers  82/78, high-dose plus beta-blockers  88/72; p
Table 4. Relative Risk of Events by Treatment
Odds R
Beta-blockers
Overall 0.71
ACE genotype
II 0.97
ID 0.85
DD 0.47
High-dose ACE inhibitors
Overall 0.86
ACE genotype
II 1.35
ID 0.88
DD 0.75
High-dose ACE inhibitors
(subject not on beta-blockers)
Overall 0.88
ACE genotype
II 1.31
ID 0.86
DD 0.62
ACE  angiotensin-converting enzyme.
igure 4. (A) Transplant-free survival by treatment strategy, DD genotype
nly (n  128, p  0.001). (B) Transplant-free survival by treatmentd
trategy, ID and II genotypes combined (n  300, p  0.38). ACE 
ngiotensin-converting enzyme; Beta  beta-blockers.0.38) (Fig. 4B). The statistical interaction of therapy with
CE genotype was of greater magnitude when ACE
nhibitor dose and beta-blocker use were considered jointly
overall interaction significant, p  0.03) (Fig. 4) than for
nalysis of either beta-blocker use (p  0.08) (Figs. 1B and
C) or ACE dose alone (p 0.25, Fig. 2; p 0.16, Fig. 3).
ISCUSSION
his study demonstrates a pharmacogenetic interaction
etween the ACE D/I polymorphism and the impact of
CE inhibitor dose on heart failure survival. In addition,
his study reconfirms in a larger cohort the previously
eported interaction between the ACE-D allele and the
ffectiveness of beta-blocker therapy. Of the estimated 5
illion Americans with heart failure (18), approximately 1.5
o 2 million are predicted to have the ACE DD genotype.
hese findings suggest that this genetic subset obtains the
aximal survival benefit from increasing levels of neurohor-
onal inhibition, and that this common polymorphism can
e potentially utilized to tailor heart failure therapy.
High-dose ACE inhibitor therapy has been shown to
educe hospitalization (19) and improve functional capacity
20) for patients with heart failure; however, efforts to
urther augment improvements in survival with high-dose
herapy have not been successful. The Assessment of Treat-
ent with Lisinopril And Survival (ATLAS) trial (4)
ompared the effects of low-dose (2.5 to 5 mg daily of
isinopril) versus high-dose ACE inhibitor therapy (32.5 to
5 mg daily) in a prospective randomized study of more
han 3,000 subjects with heart failure. Although a signifi-
ant reduction in heart failure hospitalization was evident
ith high-dose therapy, the impact on survival was modest
8% reduction in the risk of death, p  0.128) and
omparable to the current study despite a much greater dose
95% Confidence Interval p Value
(0.53, 0.96) 0.027
(0.47, 2.03) 0.94
(0.55, 1.31) 0.46
(0.28, 0.79) 0.004
(0.64, 1.16) 0.33
(0.63, 2.85) 0.44
(0.57, 1.35) 0.55
(0.44, 1.27) 0.29
(0.56, 1.15) 0.24
(0.54, 3.22) 0.55
(0.51, 1.47) 0.59
(0.33, 1.17) 0.10atioifferential in the ATLAS trial. In contrast to the higher
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November 16, 2004:2019–26 ACE Polymorphism and ACE Inhibitor Therapyoses used in the randomized trial, the impact of dose may
e underestimated in the current study as the majority in the
high” subset were actually on standard-dose therapy. How-
ver, the differential treatment effects by genotype class in
ur study suggest that the genetic heterogeneity of the ACE
ene locus may have contributed to the absence of survival
enefit in the randomized trial.
Given the absence of randomization to the medical
herapy subsets, these results must be viewed as exploratory
n nature. The low-dose and standard (‘high’) dose groups
ppear comparable (Table 2), although ischemic etiology
as more prevalent in the low-dose group. Subset analysis
y etiology suggests that the increased prevalence of coro-
ary artery disease did not influence the greater impact of
he D allele in the low-dose group. Neurohormonal markers
f ACE inhibition were not assessed during this investiga-
ion, and therefore the study can not objectively compare
he degree of ACE inhibition between the high-dose and
ow-dose groups. However, despite greater reductions in
CE activity, high-dose ACE inhibitors do not have a
reater effect on neurohormone levels (21,22). Recently, a
ewly discovered homologue of the ACE gene has been
dentified which has significant cardiac expression (23) and
ppears to inactivate angiotensin II. The role of this second
CE gene in the regulation of cardiac function and the
mplication for future genetic targeting strategies remain
nknown.
Combination therapy with an ARB may be the preferred
ethod of blockade, both in terms of ventricular remodeling
24) and reductions in sympathetic activity (25). The
alsartan Heart Failure Trial (VAL-HeFT) (5) evaluated
he addition of the ARB valsartan to the standard regimen
nd found improvements in a combined end point (death or
e-hospitalization) but no significant benefit for survival
lone. Subset analysis suggested that the impact of valsartan
n survival differed markedly depending on concordant
herapy, with decreased survival in the subset on an ACE
nhibitor, ARB, and beta-blocker. This has led to specula-
ion that excessive neurohormonal blockade may actually be
armful (26) and has emphasized the need for improved
ethodologies for targeting therapies.
The competitive interaction between beta-blockers and
CE inhibitors evident in clinical trials was also demon-
trated in this analysis. The interaction of ACE inhibitor
ose and ACE genetic background was primarily in subjects
ot receiving beta-blockers (Fig. 3), consistent with previ-
us reports (12,27) that beta-blockers diminish the impact
f the ACE-D allele on heart failure survival. The pharma-
ogenetic interaction of the ACE-D allele and the impact of
herapy was statistically more powerful when both beta-
locker usage and ACE inhibitor dose were included in the
nalysis (Fig. 4). While an analysis of beta-blocker dose
ould be of interest, the Carvedilol Or Metoprolol Euro-
ean Trial (COMET) has demonstrated potential differ-
nces in the clinical impact of carvedilol and metoprolol
artrate (28). This suggests beta-blockers may not be inter- 1hangeable and makes the pooling of beta-blocker data
ore complex. This study is therefore limited in its ability
o address the impact of beta-blocker dose.
The current data do support the pharmacogenetic hy-
othesis that the ACE D/I polymorphism modulates the
ffect of heart failure therapy in a manner consistent with
he known effect of the D allele on ACE activity. This
ypothesis can only be truly evaluated in the context of a
linical trial, and these findings should be confirmed in
andomized studies before the development of pharmaco-
enetic targeting strategies. The results of this study
trongly support the need for randomized pharmacogenetic
rials and suggest that genetic assessment of therapeutic
fficacy should be incorporated into all future pharmaceuti-
al trials. If the current findings are confirmed, one-third of
eart failure patients with the DD genotype could be
elected for more aggressive neurohormonal therapy. Fur-
her investigations will hopefully clarify the role of ACE
enotyping in the clinical management of patients with
eart failure.
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